Phoenix Financial Ltd. boosted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 57.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 30,861 shares of the healthcare product maker’s stock after buying an additional 11,287 shares during the quarter. Phoenix Financial Ltd.’s holdings in Abbott Laboratories were worth $3,050,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the company. Danica Pension Livsforsikringsaktieselskab boosted its stake in Abbott Laboratories by 30.7% during the third quarter. Danica Pension Livsforsikringsaktieselskab now owns 867,163 shares of the healthcare product maker’s stock worth $85,702,000 after buying an additional 203,662 shares in the last quarter. Danske Bank A S raised its stake in shares of Abbott Laboratories by 32.8% in the 3rd quarter. Danske Bank A S now owns 1,210,066 shares of the healthcare product maker’s stock valued at $119,591,000 after buying an additional 298,974 shares in the last quarter. Dogwood Wealth Management LLC raised its stake in shares of Abbott Laboratories by 15.4% in the 3rd quarter. Dogwood Wealth Management LLC now owns 705 shares of the healthcare product maker’s stock valued at $70,000 after buying an additional 94 shares in the last quarter. Cornerstone Advisory LLC raised its stake in shares of Abbott Laboratories by 13.8% in the 3rd quarter. Cornerstone Advisory LLC now owns 6,596 shares of the healthcare product maker’s stock valued at $652,000 after buying an additional 799 shares in the last quarter. Finally, McElhenny Sheffield Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 1.2% during the 3rd quarter. McElhenny Sheffield Capital Management LLC now owns 13,173 shares of the healthcare product maker’s stock worth $1,302,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on ABT. TD Cowen decreased their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, October 22nd. Citigroup cut their price target on shares of Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Finally, BTIG Research decreased their price objective on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.32.
Get Our Latest Research Report on ABT
Abbott Laboratories Stock Up 0.1%
Shares of NYSE ABT opened at $108.59 on Monday. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The business has a fifty day moving average of $103.93 and a two-hundred day moving average of $101.74. The stock has a market cap of $188.08 billion, a PE ratio of 40.52, a PEG ratio of 1.90 and a beta of 0.54.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.30 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is 94.03%.
Insider Buying and Selling
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the sale, the executive vice president directly owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.46% of the stock is currently owned by company insiders.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
